

## CITATION OF PRIOR ART

Sheet 1 of 2

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800 (O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation DPC	
		FILING DATE 1996 June 5, 1995	GROUP 1211

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Cp	4,141,973	02-1979	Balazs			
Cp	4,582,865	04-1986	Balazs et al.			
Wn	4,636,524	01-1987	Balazs et al.			
Wn	4,711,780	12-1987	Fahim			
Wn	4,725,585	02-1988	Wenge et al.			
Wn	4,736,024	04-1988	Della Valle et al.			
Cp	4,755,544	07-1988	Makino et al.			
Wn	4,795,741	01-1989	Leshchner et al.			
Ln	4,801,619	01-1989	Lindblad			
Wn	4,808,576	02-1989	Schultz et al.			
Cp	4,814,176	03-1989	Makino et al.			
Wn	4,840,941	06-1989	Ueno et al.			
Wn	4,851,521	07-1989	della Valle et al.			
Cp	4,937,254	06-1990	Sheffield et al.			
Wn	4,957,744	09-1990	della Valle et al.			
Wn	4,965,353	10-1990	della Valle et al.			
Cp	4,970,298	11-1990	Silver et al.			
	07/338,106	04-1989	Falk			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
Cp	1,205,031	05-1986	Canada			
Cp	1,240,929	08-1988	Canada			
Cp	0 138 572	04-1985	Europe			
Cp	0 179 442	04-1986	Europe			
Cp	0 197 718	10-1986	Europe			
Cp	0 208 623	01-1987	Europe			
Cp	0 216 453	04-1987	Europe			
Cp	0 224 987	06-1987	Europe			

\*This was taken from Application Serial No.07/675,908

FORM PT0-1449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-2	APPLICATION SERIAL NO. 08/462,148		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation				
		21 JUN 1995	FILED DATE	GROUP 1211		
FOREIGN PATENT DOCUMENTS 10096						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
1a	0 240 098	10-1987	Europe			
1b	0 265 116	04-1988	Europe			
1c	0 270 317	06-1988	Europe			
1d	0 285 357	10-1988	Europe			
1e	0 287 210	10-1988	Europe			
1f	0 295 092	12-1988	Europe			
1g	0 296 740	12-1988	Europe			
	63/045223		Japan - English translation will follow			
1h	61000017	01-1986	Japan - English translation will follow			
	WO 88/07060	09-1988	PCT			
	WO 89/07932	09-1989	PCT			
	WO 91/04058	04-1991	Int'l Search Report			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1p	Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", July 8, 1989 edition of the Globe and Mail, Toronto, Ontario, Page D4.
1r	Pam Harrison, "Toxic drug tamed but still potent" <u>Ontario Medicine</u> , Volume 8, No. 16 dated August 21, 1989, Page 1.
1s	<u>The Merck Index</u> Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, Pages 751 and 752.
1t	Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, <u>Immunity to Cancer II</u> (will follow)
1u	Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, <u>Augmentive Agents in Cancer Therapy</u> , Raven Press, New York, (1981) (will follow)
1v	Dr. Samuel Asculai, " <u>Inactivation of Herpes Simplex Viruses by Nonionic Surfactants</u> ", <u>Antimicrobial Agents and Chemotherapy</u> , April 1978, pp. 686-690. (will follow)

EXAMINER	DATE CONSIDERED
1p, 1r	6-8-96

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
P-0800(O)-2SERIAL NO.  
08/462,148

APPLICANT

Hyal Pharmaceutical Corporation

FILED DATE  
June 5, 1995GROUP  
1211

## REFERENCE DESIGNATION

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENr NUMBER	DATE	NAME	CASS	SUBCLASS	FILE DATE APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENr NUMBER	DATE	COUNTRY	CASS	SUBCLASS	TRANSLATION YES NO
AN	2,051,173	1980	FR			
AN	0,311,727	1981	EP			
AN	7,012,673	1981	DE			
AO						
AP						

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	
AS	
AT	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with  
MPEP 609; Draw line through citation if not in conformance and not considered. Include copy  
of this form with next communication to applicant.

Information Disclosure Statement—Section 9 PTO-1449 (Modified) [6-1]—page 1 of 1

\*This was taken from Application Serial NO. 07/675,908

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
P-0800(O)-2SERIAL NO.  
08/462,148

## APPLICANT

Byal Pharmaceutical Corporation

FILING DATE  
June 5, 1995

GROUP 1211

## REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR		
AS		
AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Information Disclosure Statement—Section 9 PTO-1449 (Modified) [6-1]—page — of —)

This was taken from Application Serial No. 07/675,908

FORM PTO-1449 <small>(Rev. 2-22)</small>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-2	SERIAL NO. 08/462,148
Information Disclosure Statement by Applicant		APPLICANT Hyal Pharmaceutical Corporation	
(Use several sheets if necessary)		BILING DATE June 5, 1995	GROUP 1211

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
19	AUB14534/88	11/10/90	Australia			
60	WO88/07060	09/22/88	PCT			
62	AUB17459/88	12/15/88	Australia			
61	WO89/05645	06/29/89	PCT			
62	62-201825	09/05/87	Japan (English Translation)			
62	62-287041	11/17/89	Japan (English Translation)			

## **OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner	G. Peeler	Date Considered	6-6-96
----------	-----------	-----------------	--------

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# CITATION OF PRIOR ART

Sheet 1 of 6

FORM PTO-1449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DATE 1990	DOCKET NO. P-0800(O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				TRADEMARK	APPLICANTS Hy-1 Pharmaceutical Corporation	
					FILING DATE June 5, 1995	GROUP 1211


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
lm	2,583,096	01 1952	Hadian et al			
ls	3,436,454	04-1969	Nouvel			
ly	3,887,703	06-1975	Manoussos et al			
ly	4,272,522	06-1981	Balazs			
un	4,716,224	12-1987	Sakurai et al.			
ly	4,853,226	08-1989	Machida et al.			
ly	4,946,870	08-1990	Partain, III. et al.			

## FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation YES      NO
B-72117/87	12-1987	Australia			
B-17459/88	12-1988	Australia			
30806/84	07-1984	Australia			
0,378,852	12-1989	Europe			
1,283,892	08-1972	Great Britain			
2,099,826-A	12-1982	Great Britain			
A-1116678/88 Application	11-1989 Laid-Open-to-Public	Japan			Yes
61-233,622	10-1986	Japan			No
57-183,707	12-1982	Japan			Yes
2,364,373	10-1975	Germany			Yes

\*This was taken from Application Serial No. 07/675,908

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. M-10800(0)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		 <b>APPLICANT</b> <b>12</b> <b>Hyal Pharmaceutical Corporation</b>	
		SEARCHED INDEXED JUN 5 1995	GROUP 1211

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

17	Alaverdyan MI, Ter-Avetisyan AT. <b>Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia.</b> <i>Bulletin of Experimental Biology and Medicine</i> 1967; 64(9): 967-969.
17	Balazs EA, Gibbs DA. <b>The rheological properties and biological function of hyaluronic acid.</b> In: <i>Chemistry and Molecular Biology of the Intercellular Matrix. Volumes III.</i> New York: Academic Press, 1970. PP. 1241-1253.
17	Balazs EA, Band P. <b>Hyaluronic acid: Its structure and use.</b> <i>Cosmetics &amp; Toiletries . Polymers in Cosmetics</i> 1984; 99: 65-72.
17	Camber O, Lundgren P. <b>Diffusion of some low molecular weight compounds in sodium hyaluronate.</b> <i>Acta Pharmaceutica Suecica</i> 1985; 22(6): 315-320.
17	Camber O, Edman P, Gurny R. <b>Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits.</b> <i>Current Eye Research</i> 1987; 6(6): 779-784.
17	Chang S-C. <b>Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit.</b> <i>Dissertation Abstracts International</i> 1988; 49(2): 367-B.

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION 1996 (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

Up	Cravioto, R.O., et al. <b>Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels</b> <i>Science</i> (1950); Vol. 111: 520-521
Up	Gieldanowski, Jerzy; Skowronska, Jadwiga <b>Studies on immunosuppressive and anti-inflammatory effect of adriamycin.</b> <i>Arch. Immunol. Ther. Exp.</i> (1980); 28 (3): 439-446
Up	Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. <b>Effects of adjuvants to local anaesthetics on their duration.</b> <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 384-388.
Up	Hurd ER <b>Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate.</b> <i>Arthritis and Rheumatism</i> (1973 Jan-Feb); 16 (1): 84-88
Up	Idson B. <b>Polymers in skin cosmetics.</b> <i>Cosmetics &amp; Toiletries</i> 1988; 103: 63-68.
Up	Johansson A, Hassan H, Renck H. <b>Effects of adjuvants to local anaesthetics on their duration.</b> <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 736-738.
Up	Kalbhen D.A. <b>The inhibitory effects of steroid and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®).</b> <i>Z. Rheumatol</i> (1982); 41: 202-211

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS <b>Hyal Pharmaceutical Corporation</b>	
		FILING DATE June 5, 1995	GROUP 1211

*TRADEMARKS*

<i>ly</i>	Katsu M., Abe T., Shimada S. <b>Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence.</b> <i>Nippon Rinsho</i> (1968 Jan); 26(1): 89-95
<i>ly</i>	Kreis H, Chkoff N, Droz D, et al. <b>Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients.</b> <i>Transplantation</i> (1984 Feb.); 37(2): 139-145
<i>ly</i>	McIlwraith W. <b>Current concepts in equine degenerative joint disease.</b> <i>Journal of the American Veterinary Medical Association</i> 1982; February 1: 239-250.
<i>ly</i>	Mizushima, Y. <b>Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future.</b> <i>Nippon Rinsho</i> (Jan. 1986); 26(1): 61-65
<i>ly</i>	Nizolek DJH, White KK. <b>Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review.</b> <i>The Cornell Veterinarian</i> 1981; 71(4): 355-375.
<i>ly</i>	Pigman W, et al. <b>Acide hyaluronique et facteurs de perméabilité tissulaire.</b> <i>Bull. Soc. Chim. Biol.</i> 1963; 5(2-3): 185-202.
<i>ly</i>	Pruett RC, Schepens CL, Constable IJ, Swann DA. <b>Hyaluronic acid vitreous substitute.</b> In: <i>Vitreous Surgery and Advances in Fundus Diagnosis and Treatment</i> . Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55. pp. 433-444.

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS <b>Hyal Pharmaceutical Corporation</b>	
		FILING DATE 1995 June 5, 1995	GROUP 1211

67	Reim M, Teping C. <b>Surgical procedures in the treatment of most severe eye burns.</b> <i>Acta Ophthalmologica</i> 1989-Supplementum 192; 67: 47-54.
67	Rydell NW, Balazs EA. <b>Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation.</b> <i>Clinical Orthopaedics and Related Research</i> 1971; 80(October): 25-29.
67	Saba P, Galeone F, Salvadorini F, Guarugaglini M, Ombrato M. <b>Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex.</b> <i>Current Therapeutic Research</i> 1978; 23(4): 455-463.
67	Stegman R, Miller D. <b>Use of sodium hyaluronate in severe penetrating ocular trauma.</b> <i>Acta Ophthalmol.</i> 1986; 18: 9-13.
67	Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. <b>Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid.</b> <i>Pharmatherapeutica</i> 1988; 5(4): 233-239.
67	Sertoli P, Merello A, Parodi M. <b>L'acido jaluronico, per uso topico, nella cura delle ulcere trofocircolatorie degli arti inferiori. (Comunicazioni).</b> <i>Giornale Italiano di Dermatologia</i> 1970; 45(8): 468-471.
67	Walther, M. <b>The Prevention of Striae Cutis Distansae During Pregnancy.</b> <i>Mineva Gynecologica</i> (1981) Vol. 33: 497-499

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-2	APPLICATION SERIAL NO. 08/462,148
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		APPLICANTS <b>Hyal Pharmaceutical Corporation</b>	
		FILING DATE June 5, 1995	GROUP 1211

WP	Weirich, E.G., Longauer, J.K., Kirkwood, A.H. <b>Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of salicylic acid and other drugs in animal experiments.</b> <i>Dermatologica</i> (1976); 152(2): 87-99
EXAMINER <i>L. Rech</i>	DATE CONSIDERED <i>6-696</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

## CITATION OF PRIOR ART

Sheet 1 of 1

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-6600 (O)-2	APPLICATION SERIAL NO. 08/462,148
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		1996 APPLICANT Hewitt Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,166,331	11-1992	Fidia			

## **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
↳	14534/88	11-1990	Australia			
↳	15456/88	09-1988	Australia			
↳	17459/88	08-1991	Australia			
↳	29145/89	06-1989	Australia			
	62201825		Japan - English translation			
	62287041		Japan - English translation			

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	<i>G. Perla</i>	DATE CONSIDERED <i>6-696</i>
----------	-----------------	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*This was taken from Application Serial No. 07/838,674

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

PATENT DOCKET NO.


P-0800(O)-2

SERIAL NO.

08/462,148

Information Disclosure  
Statement by Applicant

(Use several sheets if necessary)



APPLICANT

Hewitt Pharmaceutical Corporation

FILING DATE

June 5, 1995

GROUP

1211

## U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
Up	4,141,973	2/79	Balazs			
Up	4,582,865	4/86	Balazs et al.			
Up	4,636,524	1/87	Balazs et al.			
Up	4,711,780	12/87	Fahim			
Up	4,725,585	2/88	Wenge et al.			
Up	4,736,024	4/88	Della Valle et al.			
Up	4,755,544	7/88	Makino et al.			
Up	4,795,741	1/89	Leschner et al.			
Up	4,801,619	1/89	Lindblad			
Up	4,808,576	2/89	Schultz et al.			
Up	4,814,176	3/89	Makino et al.			
Up	4,840,941	6/89	Ueno et al.			
Up	4,851,521	7/89	della Valle et al.			
Up	4,937,254	6/90	Sheffield et al.			
Up	4,957,744	9/90	della Valle et al.			

## FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES / NO
Up	0 138 572	4/85	Europe			
Up	0 179 442	4/86	Europe			
Up	0 197 718	10/86	Europe			
Up	0 208 623	1/87	Europe			
Up	0 216 453	4/87	Europe			
Up	0 224 987	6/87	Europe			
Up	0 240 098	10/87	Europe			
Up	0 265 116	4/88	Europe			

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Up	Blakeslee, S., "Solid cores of tumors keeping out best drugs", July 8, 1989 edition of The Globe and Mail, Toronto, Ont., p. D4	A
Up	Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine, Vol. 8, No. 16, 8/21/89, p. 1	A
Up	The Merck Index, Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751-752	A
Up	Braun, DP et al., "Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists", Immunity to Cancer II, 1989, pp 439-448, Alan R. Liss, Inc.,	A + B

Examiner	<i>G. Rehder</i>	Date Considered	<i>6/6-96</i>
----------	------------------	-----------------	---------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
ATTY. DOCKET NO.  
PTO-900(0)-2SERIAL NO.  
08/462,148Information Disclosure  
Statement by Applicant

(Use several sheets if necessary)

27 DEC 1996 Hyatt Pharmaceutical Corporation

TRADEMARK FILING DATE  
June 5, 1995

GROUP 1211

## U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
LP	4,965,353	10/90	della Valle et al.			A
LP	4,970,298	11/90	Silver et al.			A
LP	4,684,627	8/87	LeVeen et al.			A
LP	4,303,676	12/81	Balazs			A
LP	5,166,331	11/92	della Valle et al.			E
LP	5,095,037	3/92	Iwamitsu et al.			E
LP	2,583,096	1/52	Hididian et al.			F
LP	3,436,454	4/69	Nouvel			F
LP	3,887,703	6/75	Manoussos et al.			F
LP	4,272,522	6/81	Balazs			F
LP	4,716,224	12/87	Sakurai et al.			F
V	4,853,226	8/89	Machida et al.			F
LP	4,946,870	8/90	Partain, III, et al.			F

## FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
LP	0 270 317	6/88	Europe			P
LP	0 285 357	10/88	Europe			P
LP	0 287,210	10/88	Europe			P
LP	0 295 092	12/88	Europe			P
LP	0 296 740	12/88	Europe			P
	0 312 208		Europe (abstract only)			P
LP	0 341 745	5/89	Europe			P
LP	0 244 718	4/87	Europe			P
LP	0 378,852	7/90	Europe			P

OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, Etc.)

LP	o	Goodwin, J.S., Prostaglandin E and Cancer Growth: Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, <u>Augmentive Agents in</u>	A
		Cancer Therapy, Raven Press, New York (1981), pp 393-415	
LP		Asculai, Dr. S., "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", Antimicrobial Agents and Chemotherapy, 4/78, pp. 686-690	A
		Sneader, W.E., Chemical Abstracts, vol. 76, no. 10, "Possible Mechanism for Action of DMSO on Percutaneous absorption, I. Pharm. Pharmacol, 1971, 23 (Supp)	A

Examiner	<i>R. Parker</i>	Date Considered	6-6-96
----------	------------------	-----------------	--------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	FATY. DOCKET NO. <b>P-0800(O)-2</b>	SERIAL NO. <b>08/462,148</b>
<b>Information Disclosure Statement by Applicant</b> <small>(Use several sheets if necessary)</small>			<b>APPLICANT</b> <b>HydroPharmaceutical Corporation</b>	
			<b>PPILING DATE</b> <b>June 5, 1995</b>	<b>GROUP</b> <b>1211</b>

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Exmr Inventor	Document Number	Date	Country	Class	Sub Class	Translation YES   NO
1a	1,205,031	5/86	Canada			
1a	1,240,929	8/88	Canada			
1a	2,031,880	12/90	Canada			
1a	63/045223	2/88	Japan (w/abstract)			
1a	61000017	1/86	Japan (w/abstract)			
1a	1287041		Japan (abstract only)			
1a	62201825	1987	Japan (w/abstract)			
1a	62201825	9/87	Japan (translation)			X
1a	62287041	11/89	Japan (translation)			X
1a	A11678/88	5/88	Japan (laid open) (see 1-287041 above)			X
1a	61-233622	10/86	Japan (w/ abstr)			X
1a	57-183707	11/82	Japan (translation) (corrected date)			X

## **OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, Etc.)

↳		International Preliminary Examination Report for PCT/CA90/00306 and attachement substitute claims	D
↳		Alaverdyan et al., "Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia".	F
↳		Bulletin of Experimental Biology & Medicine 1967: 64(9): 967-969	
↳		Balazs et al. "The rheological properties and biological funtion of hyaluronic acid".	F
↳		Chem. and Mol. Biol. of the Intercellular Matrix, Vol. 3, 1970, pp 1241-1253	

Examiner	<i>L. B. G.</i>	Date Considered	6-6-96
----------	-----------------	-----------------	--------

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
P-0800(O)-2SERIAL NO  
08/462,148Information Disclosure  
Statement by Applicant

(Use several sheets if necessary)



APPLICANT

HESKILL PHARMACEUTICAL CORPORATION

FILING DATE  
June 5, 1995GROUP  
1211

## U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date

## FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
LP	AUB14534/88	11/90	Australia (corrected date)			E
LP	AUB17459/88	12/88	Australia			E
LP	B-72117/87	12/87	Australia			F
LP	B-17459/88	12/88	Australia			F
LP	30806/84	7/84	Australia			F
LP	769,287	3/57	UK			C
LP	1,283,892	8/72	GB			F
LP	2,099,826-A	12/82	GB			F
LP	2364373	10/75	Germany			F
LP	WO88/07060	9/88	PCT			A
LP	WO89/07932	9/89	PCT			A
LP	WO91/04058	4/91	Intern'l Search Report (corresponds to U.S. Appl.)			A
LP	WO88/07060	9/88	PCT (submitted twice)			E
LP	WO89/05645	6/89	PCT			E

OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, Etc.)

LP		Balezs E.A. et al. "Hyaluronic acid: Its structure and use", Cosmetics &	F
		Toiletries, Polymers in Cosmetics 1984; 99: 65-72	F
LP		Camber O. et al, "Diffusion of some low molecular weight compounds in sodium hyaluronate", Acta Pharmaceutica Suecica 1985; 22(6): 315-320	F
			F
LP		Camber O. et al, "Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits", Current Eye Research 1987; 6(6): 779-784	F
			F
LP		Chang S-C, "Prodrug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit", Dissertation Abstracts International 1988; 49(2): 367-B	F
			F

Examiner

*L. Rehle*

Date Considered

6/6/95

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEU.S.  
ATTY. DOCKET NO.  
1290800(0)-2SERIAL NO.  
08/462,148Information Disclosure  
Statement by Applicant

(Use several sheets if necessary)

HYAL PHARMACEUTICAL CORPORATION

FILING DATE  
June 5, 1995GROUP  
1211OTHER DOCUMENTS  
(Including Author, Title, Date, Pertinent Pages, Etc.)

u		Cravioto R O et al, "Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid from Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); Vol. 111: 520-521	F
u		Gieldanowski J et al, "Studies on immunosuppressive and anti-inflammatory effects of adriamycin", Arch. Immunol. Ther. Exp. (1980); 28(3): 439-446	F
u		Hassan, H.G., et al., "Effects of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29: 384-388	F
u		Hurd, E.R., "Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate", Arthritis and Rheumatism (1973 Jan/Feb); 16(1): 84-88	F
u		Idson B, "Polymers in skin cosmetics", Cosmetics & Toiletries 1988; 103: 63-68	F
u		Johansson A. et al, "Effects of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29: 736-738	F
u		Kalbhen D.A., "The inhibitory effects of steroid and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®)", Z. Rheumatol (1982); 41: 202-211	F
u		Katsu M. et al., "Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence", Nippon Rinsho (1986 Jan) 26(1): 89-95	F + G
u		Kreis H et al, "Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients" Transplantation (1984 Feb); 37(2): 139-145	F
u		McIlwraith W, "Current concepts in equine degenerative joint disease", Journal of the Am. Veterinary Medical Assoc. 1982; Feb 1, vol. 180: 239-250	F
u		Mizusima Y., "Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future", Nippon Rinsho (Jan 1986); 26(1): 61-65	F
u		Nizolek D.J.H. et al, "Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A Review" The Cornell Veterinarian 1981; 71(4): 355-375	F
u		Pigman W et al, "Acide hyaluronique et facteurs de permeabilite tissulaire" Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202	F
u		Pruett RC, et al, "Hyaluronic acid vitreous substitute", In: Vitreous Surgery and Advances in Fundus Diagnosis and Treatment. H. McKenzie Freeman et al Editors, Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444	F
u		Reim M et al, "Surgical procedures in the treatment of most severe eye burns" Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54	F

Examiner

C. Reim

Date Considered

6-6-96

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. DEC E-9800(O)-2	SERIAL NO. 08/462,148
<p><b>Information Disclosure Statement by Applicant</b></p> <p>(Use several sheets if necessary)</p>		 <p>1995 APPLICANT Final Pharmaceutical Corporation</p>		
		FILING DATE June 5, 1995	GROUP 1211	

**OTHER DOCUMENTS**  
**(Including Author, Title, Date, Pertinent Pages, Etc.)**



Examiner	G. Pfeifer	Date Considered	6/6/66
----------	------------	-----------------	--------

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.